Chung-Mao Kao

Dr. Chung-Mao Kao

Taichung Veterans General Hospital, Taichung, Taiwan
orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Chung-Mao KaoChung-Mao Kao
Chung-Mao Kao
JWJun-Sing Wang
Jun-Sing Wang
WHWei-Li Ho
Wei-Li Ho
TKTai-Ming Ko
Tai-Ming Ko
HCHsian-Min Chen
Hsian-Min Chen
HCHsin-Hua Chen
Hsin-Hua Chen
Background: Potential risk factors for major adverse cardiovascular events (MACE) in patients with ankylosing spondylitis (AS) requiring medical therapy should be investigated. Methods: We identified newly diagnosed AS patients without previous MACE from 2004 to 2012 using the National Health Insurance Research Database, matched MACE cases with non-MACE controls at a 1:4 ratio for age, gender, AS duration, and index date, and included 947 AS patients with MACE and 3896 matched controls for final analyses. By using conditional logistic regression analyses, we examined the associations of MACE with low income, urbanisation, comorbidities, common extra-articular manifestations (EAM), and medications, including nonsteroidal anti-inflammatory drugs (NSAID) of three categories (traditional NSAIDs, selective cyclooxygenase-2 inhibitors (COX-2i), and preferential COX-2is) with their annual cumulative defined daily dose (cDDD) within a year before MACE development. Results: MACE development was associated with the use of selective COX-2is (especially with annual cDDD > 132) and corticosteroids, residence in rural regions, and well-known associated comorbidities, but not with the use of traditional NSAIDs, preferential COX-2i, biologics, methotrexate, sulfasalazine, and common EAMs. Conclusions: The risk factors of MACE in newly diagnosed AS patients include residence in rural regions, well-known associated comorbidities, and the use of corticosteroids and selective COX-2is. A major limitation was the lack of information on individual lifestyle patterns and disease activity.

12 March 2025 in Therapeutic Advances in Musculoskeletal Disease
Verified
Journal Article
Open access
Chung-Mao KaoChung-Mao Kao
Chung-Mao Kao
YCYen-Ju Chen
Yen-Ju Chen
YCYi-Ming Chen
Yi-Ming Chen
Der-Yuan ChenDer-Yuan Chen
Der-Yuan Chen
HCHsin-Hua Chen
Hsin-Hua Chen
Background: Rheumatoid arthritis (RA) is complicated by a high risk of cardiovascular disease and requires the initiation of biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs) for persistently active disease despite first-line therapies. The influence of b/tsDMARDs, especially tsDMARDs, on cardiovascular risk in Taiwanese patients with RA remains unclear. Objectives: To compare the risk of major cardiovascular adverse events (MACEs) or venous thromboembolism (VTE) amongst RA patients initiating approved b/tsDMARDs for up to 5 years. Design: A nationwide, population-based, retrospective cohort study. Methods: Using Taiwan National Health Insurance (NHI) Research Database, we identified patients with RA initiating NHI-reimbursed b/tsDMARDs indicated for RA between 2001 and 2020. Study outcomes were newly developed MACEs or VTE within 5 years of the first b/tsDMARD initiation. Time-dependent Cox regression analysis was performed to determine the association between b/tsDMARDs and MACEs or VTE and independently associated or protective factors. Subgroup analyses by age at b/tsDMARD initiation and cardiovascular risk levels, as well as sensitivity analyses of b/tsDMARD initiation after 2012, were performed. Results: We enrolled 12,332 adults with RA initiating the first b/tsDMARD during pre-determined period. The incidence rates of MACE and VTE were 894 and 283 per 100,000 person-years, respectively. After adjustment, other b/tsDMARDs were not associated with a higher risk of MACEs or VTE than tumour necrosis factor inhibitors (TNFis) up to 5 years after initiation. Subgroup analyses by age at b/tsDMARD initiation and cardiovascular risk levels revealed consistent findings. Factors associated with or protective against MACEs or VTE were identified. Conclusion: No non-TNFi b/tsDMARD had a higher risk of MACEs or VTE than TNFis up to 5 years after initiation amongst patients with RA, and this remained consistent for those initiating their b/tsDMARD at age 65 years and older or with high cardiovascular risk.

12 December 2025 in Seminars in Arthritis and Rheumatism
Verified
Journal Article
Closed access
Chung-Mao KaoChung-Mao Kao
Chung-Mao Kao
YCYi-Hsing Chen
Yi-Hsing Chen
WHWen-Nan Huang
Wen-Nan Huang
THTsu-Yi Hsieh
Tsu-Yi Hsieh
CHChia-Wei Hsieh
Chia-Wei Hsieh
HCHsin-Hua Chen
Hsin-Hua Chen

1 July 2025 in Lupus Science & Medicine
Verified
Journal Article
Open access
WHWan-Yun Hsu
Wan-Yun Hsu
LTLi-Yun Tsai
Li-Yun Tsai
ICI-Chieh Chen
I-Chieh Chen
JCJun-Peng Chen
Jun-Peng Chen
KCKai-Ting Chen
Kai-Ting Chen
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
Objective: To characterise the age-related impact of organ damage patterns on health-related quality of life (HRQoL) in patients with SLE and to identify specific damage patterns affecting physical and mental health outcomes across different age groups. Methods: In this cross-sectional study, 1149 patients with SLE from the Asia Pacific Lupus Collaboration cohort were stratified by age. HRQoL was assessed using the Short Form-36 questionnaire. Clinical characteristics and organ damage (Systemic Lupus International Collaborating Clinics (SLICC) Damage Index) were evaluated. Multiple linear regression analyses identified factors associated with the Physical (PCS) and Mental Component Summary (MCS) scores. Results: Significant age-related differences were observed in physical HRQoL, with the age group ≥50 years showing lower PCS scores (median 52.6) than the age groups <20 years (56.9) and 20–50 years (57.5) (p<0.001). In multivariable models, higher SLICC Damage Index (β=−1.39), lower educational attainment (β=−7.02) and prednisolone use (β=−1.85) were independently associated with lower PCS scores. MCS scores were positively associated with male gender (β=4.40) and secondary education (β=2.46), but negatively impacted by higher damage index (β=−0.90) and cyclophosphamide use (β=−5.44). Specific damage patterns, such as avascular necrosis, particularly impaired bodily pain and physical functioning domains. Conclusion: Age-related differences in SLE predominantly affect physical rather than mental aspects of HRQoL. Cumulative organ damage remains a central modifiable factor associated with poorer outcomes across all ages. These findings emphasise the importance of age-specific management strategies and early damage prevention to optimise long-term HRQoL in patients with SLE.

27 July 2026 in Lupus Science & Medicine
Verified
Journal Article
Open access
PDF file
WHWan-Yun Hsu
Wan-Yun Hsu
LTLi-Yun Tsai
Li-Yun Tsai
CLChing-Yi Lai
Ching-Yi Lai
JCJun-Peng Chen
Jun-Peng Chen
Chung-Mao KaoChung-Mao Kao
Chung-Mao Kao
Yi-Ming ChenYi-Ming Chen
Yi-Ming Chen
Objective: Fibromyalgia (FM) frequently co-occurs with SLE, but its independent contribution to musculoskeletal risk is unclear. We aimed to determine whether comorbid FM is independently associated with the risk of falls, recurrent falls, thoracolumbar vertebral fractures and osteoporotic fractures in patients with SLE. Methods: We conducted a propensity score-matched (PSM) retrospective cohort study using the TriNetX US Collaborative Network. Adult SLE patients with comorbid FM (SLE+FM) were matched 1:1 to SLE patients without FM (SLE-only) on demographics, comorbidities, laboratory parameters and 19 medications. A 6 month washout period preceded outcome ascertainment to ensure capture of incident events only. Time-to-event analyses over 5 years for risk of falls, recurrent falls, thoracolumbar vertebral fractures and osteoporotic fractures used Kaplan-Meier curves and Cox proportional hazards regression. Results: After 1:1 PSM, 23 775 matched pairs were retained with substantially improved covariate balance. At 5 years, SLE+FM patients had significantly elevated risks of incident falls (adjusted HR (aHR) 1.38, 95% CI 1.29 to 1.48), recurrent falls (aHR 1.53, 95% CI 1.32 to 1.76), thoracolumbar vertebral fractures (aHR 1.18, 95% CI 1.01 to 1.37) and osteoporotic fractures (aHR 1.14, 95% CI 1.02 to 1.27) compared with the SLE-only group. Associations were directionally consistent at 3 years and across all prespecified subgroups. Kaplan-Meier curves showed early and progressive divergence between cohorts from the start of follow-up. Conclusion: Comorbid FM is significantly and independently associated with increased fall and fracture risk in SLE. These findings support the incorporation of FM evaluation into fall risk assessment, alongside multidisciplinary bone-protective and fall-prevention strategies, in SLE patients with comorbid FM.